PF-Atlas › Clinical Trials › NCT00662038
Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis
pirfenidone · Phase 3
Registry ID
NCT00662038
Phase
Phase 3
Status
Completed
Drug / intervention
pirfenidone
Sponsor
Genentech, Inc.
Start
2008-08
About this trial
pirfenidone is evaluated in NCT00662038, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Genentech, Inc.. Current status: Completed.
Explore related
Related trials
Medical disclaimer. This page summarizes public trial data for NCT00662038 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.